Market Cap
$1.9B
NVCR
NovoCure Ltd
$15.26 ▼ -4.15%
Prev close $15.92Market cap$1.9B
ConsensusBuy
12-mo target$27.14 (+77.9%)
▲ Bullish
Analyst conviction 7/10
Insider Selling Cluster (8 insiders)High Impact Filing (7/10) Healthcare & Medical Devices
Snapshot
The big-picture read on NVCR right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Buy (69%)
Insider Activity
$0.00 buy / $2.8M sell
Insider Net $
-$2.8M
SEC Reports
14
Price chart 30d -14.4%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 10, 2026 short_volume
Sep 9, 2026 SEC Short Volume: NVCR — 77.5% short (0.5M / 0.6M)
Short: 493,086 | Exempt: 116 | TRF Vol: 636,326 | Short Ratio: 77.5% | Off-exchange volume (dark poo
Director Timothy Scannell retired from NovoCure's board effective September 2, 2026, after five years of service. The fi
8-K — Impact 2/10
NovoCure disclosed a cybersecurity incident from mid-August 2026 involving unauthorized access to some information syste
8-K — Impact 3/10
Novocure reported Q2 2026 net revenues of $183.6M (+16% YoY), beating consensus of $172.4M, and a GAAP EPS loss of $0.13
8-K — Impact 7/10
Jun 30, 2026 Insider
Leonard Frank X was granted 1,905 shares
Chief Executive Officer @ $11.15 ($21.2K)
Jun 30, 2026 Insider
Danziger Asaf was granted 268 shares
Director @ $11.15 ($3.0K)
Jun 30, 2026 Insider
Ben Arye Barak was granted 1,299 shares
General Counsel @ $11.15 ($14.5K)
Analyst ratings buy % -10.4%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
69% rate it Buy or better · 13 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Jul 24, 2026 | Wedbush | MAINTAIN | Neutral | 57% |
| Jul 23, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Jun 18, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| May 4, 2026 | Wells Fargo | MAINTAIN | Equal-Weight | 54% |
| May 1, 2026 | Evercore ISI Group | MAINTAIN | Outperform | 59% |
| Apr 16, 2026 | Wedbush | REITERATE | Neutral | 57% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 3 | 6 | 4 | 0 | 0 | 69% | |
| Aug 1, 2026 | 3 | 6 | 4 | 0 | 0 | 69% | |
| Jul 1, 2026 | 4 | 6 | 3 | 0 | 0 | 77% | |
| Jun 1, 2026 | 4 | 6 | 3 | 0 | 0 | 77% | |
| May 1, 2026 | 4 | 6 | 3 | 0 | 0 | 77% | |
| Apr 1, 2026 | 4 | 6 | 3 | 0 | 0 | 77% | |
| Mar 1, 2026 | 4 | 6 | 3 | 0 | 0 | 77% | |
| Feb 1, 2026 | 4 | 6 | 3 | 0 | 0 | 77% |
Price targets
Where 7 covering analysts think NVCR trades over the next 12 months.
$27.14 +77.9% upside Strong Buy
Current$15.26 Low$17.00 Median$25.00 High$52.00 7 analysts
$17.00$52.00
Analyst rating None as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
14 SEC filing reports analyzed · 2 bullish, 2 bearish, 1 mixed, 9 neutral · avg impact 4.3/10.
NEUTRAL8-K2/10
Director Timothy Scannell retired from NovoCure's board effective September 2, 2026, after five year
Sep 9, 2026
NEUTRAL8-K3/10
NovoCure disclosed a cybersecurity incident from mid-August 2026 involving unauthorized access to so
Sep 1, 2026
BULLISH8-K7/10
Novocure reported Q2 2026 net revenues of $183.6M (+16% YoY), beating consensus of $172.4M, and a GA
Jul 23, 2026
BULLISH8-K7/10
NovoCure announced that its Optune Pax device received CE Mark for the treatment of locally advanced
Jun 30, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 10, 2026
short_volume
Short Volume: NVCR — 77.5% short (0.5M / 0.6M)
Short: 493,086 | Exempt: 116 | TRF Vol: 636,326 | Short Ratio: 77.5% | Off-exchange volume (dark pool + OTC)
Sep 9, 2026
Clinical Trial
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
Phase Phase 2 — COMPLETED
Sep 8, 2026
Clinical Trial
EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma
Phase Phase 2 — COMPLETED
Sep 8, 2026
short_volume
Short Volume: NVCR — 82.7% short (0.5M / 0.6M)
Short: 474,874 | Exempt: 70 | TRF Vol: 574,018 | Short Ratio: 82.7% | Off-exchange volume (dark pool + OTC)
Aug 4, 2026
ftd
FTD: NVCR — 52,177 shares ($0.8M) failed to deliver
Settlement: 20260804, Price: $15.32, FTD Value: $799,351.64, NOVOCURE LTD ORD SHS (JEY)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.24 | $-0.32–$-0.14 | 25.8% | +0.0% | 5↑ 1↓ | $0.2B | 7 |
| Next Q | $-0.25 | $-0.31–$-0.15 | -14.2% | +0.0% | 5↑ 1↓ | $0.2B | 7 |
| Current FY | $-1.25 | $-1.39–$-1.05 | -2.5% | +0.0% | 6↑ 0↓ | $0.7B | 7 |
| Next FY | $-0.82 | $-1.33–$-0.22 | 34.7% | +0.0% | 5↑ 1↓ | $0.8B | 7 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.245 | — |
| 7d ago | $-0.245 | — |
| 30d ago | $-0.245 | — |
| 60d ago | $-0.327 | +0.082 |
| 90d ago | $-0.327 | +0.082 |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
18 insiders, 50 transactions. Net -$2.8M — $0.00 bought, $2.8M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 30, 2026 | Leonard Frank X | Chief Executive Officer | AWARD | 1,905 | $11.15 | $21.2K |
| Jun 30, 2026 | Danziger Asaf | Director | AWARD | 268 | $11.15 | $3.0K |
| Jun 30, 2026 | Ben Arye Barak | General Counsel | AWARD | 1,299 | $11.15 | $14.5K |
| Jun 30, 2026 | Puri Michal Nath | Chief Human Resources Officer | AWARD | 1,905 | $11.15 | $21.2K |
| Jun 4, 2026 | Leonard Frank X | Chief Executive Officer | SELL | 34,273 | $17.93 | $614.6K |
| Jun 3, 2026 | Ocean Allyson J | Director | AWARD | 16,999 | — | — |
| Jun 3, 2026 | LEUNG GABRIEL | Director | AWARD | 16,999 | — | — |
| Jun 3, 2026 | Madden Martin J. | Director | AWARD | 11,610 | — | — |
| Jun 3, 2026 | Hung David | Director | AWARD | 16,999 | — | — |
| Jun 3, 2026 | Stafford Kristin | Director | AWARD | 16,999 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for NVCR.
Shares short
11,796,425
Settlement Sep 15, 2026
Change vs prior
+9.3%
Semi-monthly cycle
Days to cover
11.5
At avg daily volume
Of shares outstanding
≈10.1%
Estimate — not % of float
All NVCR filing & press-release reports (14)
- 8-K reportSep 9, 2026
- 8-K reportSep 1, 2026
- 8-K reportJul 23, 2026
- 8-K reportJun 30, 2026
- 8-K reportJun 18, 2026
- 8-K reportJun 5, 2026
- CLUSTER reportJun 5, 2026
- CLUSTER reportJun 3, 2026
- DEFA14A reportApr 20, 2026
- CLUSTER reportMar 5, 2026
- CLUSTER reportMar 3, 2026
- CLUSTER reportMar 3, 2026
- 8-K reportFeb 26, 2026
- 8-K reportFeb 24, 2026